Five drugs that succeeded in insurance benefits in Korea due to Risk Sharing Agreement (RSA) have been re-contracted by lowering drug prices to the expiration of the contract.

According to the industry, the MOHW is recently pushing to revise the list of drug benefits aimed at the 1st of next month for a total of five successful drugs negotiated by the NHIS and the pharmaceutical companies. The drugs are Roche Korea's Perjeta (Pertuzumab) and Novartis' Meqsel (Trametinib Dimethyl Sulfoxide) , which will reduce existing drug prices by at least 0.5% and at most 10%.

Perjeta's prices were down 10% from ₩2,465,60 to ₩2,214,600. The price of Meqsel will be reduced from ₩128,344